Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Study sponsor: Sol-Gel Technologies, Ltd. · SLGL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-07-14Actual
Enrollment · participants108Actual
Source updated2024-09-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.